Treatment with monoclonal antibodies boosts microglial phagocytosis in Alzheimer's disease, suggesting lipid droplets may offer new therapeutic targets in neurodegenerative diseases.
Key Points
Therapeutic targets may enhance microglial function in age-related neurodegenerative diseases.
Monoclonal antibodies like lecanemab improve phagocytosis in Alzheimer's disease.
Analysis of lipid metabolism and oxidative stress highlights the role of lipid droplets in microglial health.
Targeting lipid droplets could restore energy metabolism and reduce neuroinflammation in microglia.